Back

Prevalence and clinical implications of conduction system disease in patients with cardiac transthyretin amyloidosis

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Treatment considerations in amyloidosis Clinical HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Lara Sophie Schlender

University Hospital Frankfurt, Frankfurt (Germany)

6 More presentations in this session

Presentation thumbnail
Systematic screening for transthyretic cardiac amyloidosis in patients undergoing TAVI: results from a greek-cypriot registry
Doctor T. Tsampras (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Decoding the decades: Tafamidis efficacy across different age groups in ATTR-CM patients
Doctor J. Fernandes Pedro (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Exploring tafamidis outcomes across varying disease severities in ATTR-CM
Doctor C. Gregorio (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Tafamidis and patient-reported outcomes in ATTR cardiomyopathy
Mr D. Ferreira (Lisbon, PT)
Abstract Slides Video
Presentation thumbnail
Autonomic disfunction and peripheral neuropathy assessment by TILT and EMG in cardiac amyloidosis: insights from a high-volume single center.
Doctor R. Carvalho (Lisbon, PT)
Abstract Slides Video

Access the full session

Session thumbnail
Treatment considerations in amyloidosis

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Clinical implications of cardiac implantable electronic devices in ATTR cardiomyopathy
thumbnail
Congress Presentation
Cardiac resynchronization therapy, remodeling and outcome in patients with amyloid transthyretin cardiomyopathy
thumbnail
Congress Presentation
Cardiac transthyretin amyloidosis in patients with conduction system disease

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources